Evidence map›Paper›PMID 42055283›Full record

ArticleMolecular & cellular proteomics : MCP2026

N-Glycosylation of AXL Receptor Tyrosine Kinase Regulates Its Stability, Phosphorylation, and Oncogenic Function.

Li Wang, Lingrui Li, Jidong Wang, Kishore Garapati, Feifei Li, Md Kamrul Hasan Khan, Xiangyi Kong, Hamid Bakshi, Dan Jiang, Shiya Zheng and 8 more

Abstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Li WangDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Lingrui LiDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA; Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jidong WangDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA; Department of gynecological oncology, Shandong Province Maternal and Child Healthcare Hospital, Jinan, Shandong, China.
Kishore GarapatiDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Feifei LiDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Md Kamrul Hasan KhanDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Xiangyi KongDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA; Department of Gynecology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing University Medical School, Nanjing, China.
Hamid BakshiDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Dan JiangDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Shiya ZhengDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Lifeng ChenDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Jasper YangDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA; Department of Chemistry, Carleton College, Northfield, Minnesota, USA.
Xiaonan HouDepartment of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Scott H KaufmannDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
S John WerohaDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA; Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Jing WangDepartment of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: wangjing@cicams.ac.cn.
Akhilesh PandeyDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA; Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, USA; Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India. Electronic address: Pandey.Akhilesh@mayo.edu.
Xinyan WuDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: Wu.Xinyan@mayo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

AXL, a receptor tyrosine kinase implicated in tumor progression, undergoes post-translational modifications that regulate its activity and stability. In this study, we demonstrated that AXL is extensively N-glycosylated in breast and ovarian cancer cells, existing predominantly as two isoforms corresponding to high-mannose and complex-type glycans. The extracellular cleaved soluble form of AXL (sAXL) primarily carries complex N-glycans and relies on glycosylation maturation. Functional analyses showed that complex glycosylation is essential for AXL membrane translocation and phosphorylation, as inhibition of N-glycan maturation caused cytoplasmic accumulation and impaired receptor activation. Mass spectrometry-based glycoproteomic analysis identified five glycosylation sites (N43, N157, N198, N339, and N345) with extensive microheterogeneity, including sialylation, fucosylation, and bisecting GlcNAc modifications. Evolutionary conservation analysis and mutational studies revealed that glycosylation at N43 and N339 is critical for AXL phosphorylation and cell proliferation, while multiple sites collectively contribute to protein stability and subcellular trafficking. Overall, our results demonstrate that N-glycosylation is essential for AXL stability, localization, and oncogenic signaling, offering new insights into the role glycosylation in regulating receptor tyrosine kinases function in cancer.

Indexed as

Proto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesAxl Receptor Tyrosine KinaseCell Line, TumorCell ProliferationGlycosylationHumansPhosphorylationPolysaccharidesProtein Processing, Post-TranslationalProtein StabilityProtein TransportSignal TransductionAXL protein, humanAxl Receptor Tyrosine KinasePolysaccharidesProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesAXLN-glycosylationphosphorylationproliferationproteomicsreceptor tyrosine kinase

Identifiers

PMID42055283
PMCPMC13240818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.